Low Doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after Cyclophosphamide (4 G/m2) Enhance the Peripheral Blood Progenitor Cell Harvest: Results of Two Randomized Studies Including 120 Patients

P Quittet,P Ceballos,E Lopez,Z Y Lu,P Latry,C Becht,E Legouffe,N Fegueux,C Exbrayat,D Pouessel,V Rouillé,J P Daures,B Klein,J F Rossi

DOI: https://doi.org/10.1038/sj.bmt.1705441

2006-01-01

Bone Marrow Transplantation

Abstract:The use of a combination of G-CSF and GM-CSF versus G-CSF alone, after cyclophosphamide (4 g/m2) was compared in two randomized phase III studies, including 120 patients. In study A, 60 patients received 5 × 2 μg/kg/day of G-CSF and GM-CSF compared to 5 μg/kg/day of G-CSF. In study B, 60 patients received 2.5 × 2 μg/kg/day G-CSF and GM-CSF compared to G-CSF alone (5 μg/kg/day). With the aim to collect at least 5 × 106/kg CD34 cells in a maximum of three large volume leukapherises (LK), 123 LK were performed in study A, showing a significantly higher number of patients reaching 10 × 106/kg CD34 cells (21/29 in G+GM-CSF arm vs 11/27 in G-CSF arm, P=0.00006). In study B, 109 LK were performed, with similar results (10/27 vs 15/26, P=0.003). In both the study, the total harvest of CD34 cells/kg was twofold higher in G-CSF plus GM-CSF group (18.3 × 106 in study A and 15.85 × 106 in study B) than in G-CSF group (9 × 106 in study A and 8.1 × 106 in study B), a significant difference only seen in multiple myeloma, with no significant difference in terms of mobilized myeloma cells between G-CSF and GM-CSF groups.